Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS One. 2011;6(8):e22576. doi: 10.1371/journal.pone.0022576. Epub 2011 Aug 4.
Molecular identification of a microbe is the first step in determining its prevalence of infection and pathogenic potential. Detection of specific adaptive immune responses can provide insights into whether a microbe is a human infectious agent and its epidemiology. Here we characterized human anti-IgG antibody responses by luciferase immunoprecipitation systems (LIPS) against two protein fragments derived from the capsid protein of the novel HMOAstV-C astrovirus. While antibodies to the N-terminal fragment were not informative, the C-terminal capsid fragment of HMOAstV-C showed a high frequency of immunoreactivity with serum from healthy blood donors. In contrast, a similar C-terminal capsid fragment from the related HMOAstV-A astrovirus failed to show immunoreactivity. Detailed analysis of adult serum from the United Sates using a standardized threshold demonstrated HMOAstV-C seropositivity in approximately 65% of the samples. Evaluation of serum samples from different pediatric age groups revealed that the prevalence of antibodies in 6-12 month, 1-2 year, 2-5 year and 5-10 year olds was 20%, 23%, 32% and 36%, respectively, indicating rising seroprevalence with age. Additionally, 50% (11/22) of the 0-6 month old children showed anti-HMOAstV-C antibody responses, likely reflecting maternal antibodies. Together these results document human humoral responses to HMOAstV-C and validate LIPS as a facile and effective approach for identifying humoral responses to novel infectious agents.
微生物的分子鉴定是确定其感染流行程度和致病潜力的第一步。检测特定的适应性免疫反应可以深入了解微生物是否为人类感染剂及其流行病学特征。在此,我们通过荧光素酶免疫沉淀系统(LIPS)鉴定了针对新型 HMOAstV-C 星状病毒衣壳蛋白两个蛋白片段的人抗 IgG 抗体反应。虽然针对 N 端片段的抗体没有提供信息,但 HMOAstV-C 的衣壳 C 端片段与来自健康献血者的血清具有高频率的免疫反应性。相比之下,来自相关 HMOAstV-A 星状病毒的类似衣壳 C 端片段未能显示免疫反应性。使用标准化阈值对来自美国的成人血清进行详细分析表明,HMOAstV-C 血清阳性率约为 65%。对来自不同年龄组儿童的血清样本进行评估显示,6-12 个月、1-2 岁、2-5 岁和 5-10 岁儿童的抗体阳性率分别为 20%、23%、32%和 36%,表明随着年龄的增长,抗体阳性率逐渐上升。此外,50%(11/22)的 0-6 个月大的儿童显示出抗 HMOAstV-C 抗体反应,可能反映了母体抗体的存在。这些结果共同证明了人类对 HMOAstV-C 的体液反应,并验证了 LIPS 是一种简单有效的方法,可用于鉴定针对新型感染性病原体的体液反应。